Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer facing supply constraints, and have been removed from the shortage list
The primary endpoints were the percentage change in body weight relative to baseline and the proportion of patients achieving a weight loss of 5% or more ( 4.11 SURMOUNT-CN: tirzepatide for weight loss in Chinese obese and overweight adults The SURMOUNT-CN trial recruited 210 obese or overweight adult patients in China, who received weekly doses of tirzepatide (10 mg, 15 mg) or placebo for 52 weeks
Patel DK, Stanford FC
At Klinic, we provide access to licensed healthcare professionals who evaluate and prescribe tirzepatide, which is FDA-approved and also known as Zepbound for weight management
US$ 25.68
US$ 21.01
US$ 26.75
US$ 27.31
US$ 24.60
